Treating diabetic patients with the cholesterol-lowering drug niacin does not result in increased heart attacks or mortality, despite historical evidence that niacin raises blood sugars.
Paul Canner, PhD, senior biostatistician at the Maryland Medical Research Institute, Baltimore, Maryland, United States, performed a new analysis of the data accumulated during the landmark Coronary Drug Project, which evaluated the effects of several medications on heart disease parameters.
Looking at the 6- and 15-year data, Dr. Canner said, “In the Coronary Drug Project, niacin reduced non-fatal myocardial infarctions and mortality similarly in patients at all levels of blood glucose, including those with fasting blood glucose of 126 mg/dL”.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!